Disc Medicine announced its Q1 2026 financial results, highlighting the completion of enrollment for its Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP), with topline data expected in Q4 2026. The company also plans to present updated Phase 2 data for DISC-0974 in myelofibrosis anemia at the ASCO meeting and expects data from ongoing studies of DISC-3405 in polycythemia vera and sickle cell disease by Q4 2026. Disc Medicine ended Q1 with $730 million in cash, supporting operations into 2029. These milestones position the company for multiple important catalysts later this year.
Nexans and Hydro have agreed on a five-year contract for about 85,000 tonnes of low-carbon aluminium wire rod to support Europe's electricity grid modernization. This aluminium, produced using 100% renewable energy in Norway, will help reduce carbon ...
Nexans and Hydro have agreed on a five-year supply contract for about 85,000 tons of low-carbon aluminum wire rod to support the modernization and decarbonization of Europe's electrical grid. The aluminum, produced in Norway using 100% renewable ener...
Scilex Holding Company announced a binding term sheet with Kazakhstan-based iHolding Group LLP for a $100 million investment, purchasing about 6.67 million shares at $15 each. This funding aims to support Scilex's strategic growth in healthcare, prod...
Following Shell's interim dividend payment for Q1 2026 on June 29, several senior executives, including CEO Wael Sawan and CFO Sinead Gorman, acquired shares through dividend reinvestment plans. These shares were obtained in respect of shares previou...
The global aliphatic hydrocarbon solvents and thinners market is projected to grow from $5.26 billion in 2026 to $6.81 billion by 2032, at a CAGR of 4.4%. Growth is fueled by rising demand in coatings, adhesives, and industrial maintenance, with mine...
